Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on August 18, 2007
Japanese Journal of Clinical Oncology 2007 37(9):647-651; doi:10.1093/jjco/hym084
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/9/647    most recent
hym084v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Takano, T.
Right arrow Articles by Miyauchi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takano, T.
Right arrow Articles by Miyauchi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Expression of Oncofetal Fibronectin mRNA in Thyroid Anaplastic Carcinoma

Toru Takano1,, Yasuhiro Ito2, Fumio Matsuzuka2, Akihiro Miya2, Kaoru Kobayashi2, Hiroshi Yoshida2 and Akira Miyauchi2

1 Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Osaka
2 Kuma Hospital, Kobe, Japan

For reprints and all correspondence: Toru Takano, Department of Laboratory Medicine, Osaka University Graduate School of Medicine, D2, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: ttakano{at}labo.med.osaka-u.ac.jp

Received March 7, 2007; accepted April 28, 2007

Background: Oncofetal fibronectin (onfFN) is a fetal protein, the expression of which is observed in papillary thyroid carcinomas but not in follicular tumors or in normal thyroid. Its expression in anaplastic thyroid carcinoma (ATC), however, has not been clarified, since only a few cases had been examined in previous studies.

Methods: We examined the expression levels of onfFN mRNA in ATC tissues and cell lines derived from ATC by real-time quantitative reverse transcription-polymerase chain reaction (PCR) and in situ hybridization.

Results: Increased expression of onfFN mRNA was observed in all cases of ATC regardless of the type of accompanying differentiated carcinoma and five of six ATC cell lines. Furthermore, expression of onfFN mRNA was observed in the majority of ATC cells in all six tissues examined by in situ hybridization.

Conclusion: These results confirm that expression of onfFN mRNA characterizes not only papillary thyroid carcinoma but also ATC. onfFN mRNA or protein may be a useful marker to identify anaplastic carcinoma cells and may be considered as an optimistic target in molecular-based therapy of ATC.

Key Words: molecular Dx • tumor markers • immunotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.